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Hepatopulmonary syndrome (HPS) is an uncommon complication of chronic 
liver disease and portal hypertension. It is characterised increased alveolar 
arteriolar oxygen gradient leading to hypoxemia in patients with portal 
hypertension with or without chronic liver disease. Patients with intrapulmonary 
vasodilatation (IPVD) as manifested by increased alveolar arteriolar oxygen 
differences do not always have hypoxemia known to have subclinical HPS.  
HPS do not always depend on the underlying liver disease severity. HPS have 
been described in patients with abnormal porto-caval connection without any 
evidence of chronic liver disease.  
Exact pathogenesis is still not understood. Multiple factors have been proposed 
as pathogenesis of HPS in the development of intrapulmonary vasodilatation 
(IPVD) and hypoxemia. Vasodilatory gaseous transmitters like nitric oxide 
(NO) and carbon monoxide (CO) known to play important role in the 
development of IPVD. Along with the Vasodilatory properties of NO, its role in 
the neo angiogenesis and formation intrapulmonary shunt also has been 
proposed. 
Hydrogen sulphide, originally known as environmental pollutant, most recently 
recognised as a blood flow regulator and mucosal healing properties. HS is 
synthesized from cysteine by different enzymes in different places. It has been 
studied in patients with circulatory failure and in patients with inflammatory 
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bowel disease for its mucosal healing properties. Its role in regulation of 
sinusoidal blood flow has been studies by Fiorucci et al. There is no study 
regarding its role in pathogenesis of hepatopulmonary syndrome.  
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Hepatopulmonary syndrome: 
Hepatopulmonary syndrome is a lung disorder usually found in patients with 
liver diseases, was first described long back in 1966 by Berthelot et al(1). 
Marked pulmonary vascular dilatation was noted in autopsy specimen of 
patients with cirrhosis(2). The term HPS was first coined in 1977(3). 
Reported incidence of HPS varies in different studies. It also depends on the cut 
off value of hypoxia taken into consideration(4). 10 to 30% prevalence have 
been reported from the liver transplant centre(5). In a study from India by Gupta 
et al, prevalence of HPS was much higher in patients with chronic liver disease 
than extra hepatic portal venous obstruction(6). The cut off for partial pressure 
of oxygenation and alveolar-arterial oxygen gradient, as recommended by a task 
force is mention below in the table. 
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Degree of severity  
Mild  Alveolar-arterial oxygen gradient ≥15 mm Hg, partial 
pressure of oxygen ≥80 mm Hg 
Moderate Alveolar-arterial oxygen gradient ≥15 mm Hg, partial 
pressure of oxygen ≥60 to <80 mm Hg 
Severe Alveolar–arterial oxygen gradient ≥15 mm Hg, 
partial pressure of oxygen ≥50 to <60 mm Hg 
Very severe Alveolar-arterial oxygen gradient ≥15 mm Hg, partial 
pressure of oxygen <50 mm Hg 
Table 1. Diagnostic Criteria for the Hepatopulmonary Syndrome.* 
*Adopted from ref. No 14. 
Screening for hepatopulmonary syndrome: 
Liver transplantation is the only effective treatment available in patients with 
HPS. Severity of hypoxemia also affects the mortality of patient both 
preoperatively and post operatively. Severity of hypoxemia also does not 
depend on the severity of liver disease. The American Association for the Study 
of Liver Disease Practice Guidelines recommend early referral and evaluation 
for liver transplantation in patients with HPS(7). The United Network for Organ 
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Sharing (UNOS) liver allocation policy also supports Model for End-stage Liver 
Disease (MELD) exception points to provide a patient a reasonable probability 
of being transplanted within 3 months in patients with severe HPS that is the 
partial pressure of oxygen (PaO2) is 60 mm Hg on room air(8). 
This is important as patients with hepato pulmonary syndrome may have very 
low MELD score and they may not be eligible for listing in the cadaveric listing 
programme. This signifies the importance of early detection and referral along 
with extra point allocation to the patients with HPS for liver transplantation. 
Thus, identifying these patients has clinical implications. Screening of those 
groups of patients is not always cost effective as there are no specific clinical 
findings to suggest HPS in patients with chronic liver disease. In a study by 
Roberts et al describe the mode of HPS screening and cost effectiveness of the 
same in candidates listed for liver transplantation. Author concluded that 
selective group of patients with HPS especially those are being listed for liver 
transplantation can be screened by pulse oximetry. prevalence of HPS is also 
important in deciding the utility of screening programme (9).  
 
Clinical manifestations: 
This varies from asymptomatic to oxygen dependant. Clinical features are of 
limited use in predicting HPS. Dyspnoea at rest or exertional dyspnoea may be 
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the presenting symptoms. In patients with chronic liver disease dyspnoea may 
be due to multiple factors like: anaemia, tense ascites, pleural effusion or HPS. 
Few clinical signs like spider naevi, clubbing and cyanosis have been associated 
with HPS. However presence of orthodeoxia in a patient with chronic liver 
disease strongly suggests HPS. Orthodeoxia can be measured by arterial blood 
gas analysis. 5% or more drop in the PaO2 in arterial blood when patient moves 
from the supine to standing position. Patient may describe it as platypnoea(10). 
 
 
Natural history:  
Median survival of patients with HPS is considerably lower than the age, sex, 
CTP and MELD matched cohort without liver disease. Median survival of 
patient not undergoing liver transplantation is around 24 months as compared to 
87 months without HPS(11). Similarly 5 years survival rate  also significantly 
decreased in HPS patients compared to those without HPS (63% Vs 23%)(12). 
Worse survival has been observed in severely hypoxemic that in partial pressure 
of oxygen <50%, which suggest the fact that progressive deterioration of liver 
function due to relative ischemia of the liver(13). Although the death in patients 
with HPS hardly attributed by worsening liver function rather than due to 
hypoxemia.  
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Pathogenesis:  
Three mechanisms have been described in the pathogenesis of HPS(14).  
1) Ventilation perfusion mismatch 
2) Right to left shunting 
3) Limitation in diffusion.  
Dilatation of pre-capillary and capillary vessels and increase the numbers of 
dilated vessels leading to right to left shunting and ventilation perfusion 
mismatch. Various gaseous mediators are responsible for the mechanism(15). 
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Figure 1: The pathophysiology of hepatopulmonary syndrome. (a) Represents 
normal alveoli, where oxygen diffuses from a normal alveolus into a pulmonary 
capillary. (b) Represents the exchange of gas in hepatopulmonary syndrome  
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Nitric oxide: 
Nitric oxide (NO) is synthesized by nitric oxide synthase (NOS) from L-
arginine. NO is considered as a relaxant to vascular smooth muscle cell and a 
potent vasodilator(16). The role of NO in the development of HPS has been 
studied extensively. In a study by... increase level of exhaled NO seen in 
patients with cirrhosis with HPS as compared to patients without HPS(17).  
 
Pulmonary angiogenesis: 
Along with dilatation of the pre-capillary and capillary vessels there is also 
proliferation of the new vessels around the alveolus. Increase in the TNF-α 
results in recruitment of pulmonary intravascular monocyte and activation of  
VEGF (vascular endothelial growth factor) dependent pathways are thought to 
be responsible for this(18).  
 
Endothelin 1(ET-1): 
Plasma level of ET-1 is increased in patient with HPS as compared to patients 
without HPS(19). Overexpression of endothelin B receptors have been noted 
and activation of ETb receptors result in NO induced vasodilatation(20).  
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Figure 2: Possible mechanism and therapeutic options in hepatopulmonary 
syndrome 
 
No appears to be key mediators of vasodilatation in the development of 
hepatopulmonary syndrome. In experimental HPS increase in pulmonary 
endothelin B receptors were noted in pulmonary circulation. Reasons for the 
increase in this receptos are not well understood. This may be due to stress 
secondary to portal hypertension in the pulmonary endothelium. Other 
mediators like TNF-α, released by macrophages, activates inducible NO 
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syntheses (iNOS) increase NO level in the pulmonary circulation(21). There is 
enough evidence to suggest that NO mediated vasodilatation is important in the 
HPS pathogenesis. NO is increased in patients with HPS as compared to those 
without HPS(22). Inhibition of NOS lead to improvement in oxygenation in 
patients with HPS(23). 
In addition CO (carbon monoxide) also plays a role in vasodilatation. CO is 
primarily produced by heme oxygenase (HO) from degradation of heme.  HO is 
up regulated in pulmonary macrophages, responsible for the production of CO 
in the pulmonary circulation(24). CO also mediates vasodilatation in the similar 
way  as NO by stimulating cyclic GMP production in arteriolar smooth muscle 
cells(25). 
 
Diagnossis of HPS: 
HPS should be kept in the differential diagnosis of dyspnoeic patients with liver 
disease. Approximately 50% of patients with HPS complained of dyspnoea. 
Presence of cirrhosis is also not essential for the diagnosis of HPS. HPS also has 
been diagnosed in patients with acute alcoholic hepatitis or acute budd chiari 
syndrome. Platypnoea and/or orthodeoxia may be the more specific symptoms 
in the diagnosis of HPS. Platypnoea is a type of dyspnoea that increases from 
the supine to erect position. Orthodeoxia means hypoxia that is worsening on 
erect position. But sensitivity of all this symptoms is very low(26). Finger 
clubbing is common in patients with HPS(26). Cyanosis may be noted in 
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patients with severe HPS as they become sufficiently hypoxic to appear 
cyanosed at rest. When cyanosis is combined with clubbing in a patient with 
cirrhosis, finding is highly suggestive of HPS(27).  
 
Diagnosis of HPS required the presence of hypoxia in patients with chronic 
liver disease with intrapulmonary shunt without evidence of intrinsic 
cardiorespiratory disorders. Arterial blood gas is used to demonstrate the 
evidence of hypoxia. It can be repeated after changing the position of patients to 
demonstrate orthodeoxia.  
 
Determination of hypoxemia: 
In the outpatient settings pulse oxymetry can be used to monitor and considered 
as a screening tool for HPS. The cut off value of ~97% has high sensitivity with 
moderate specificity in diagnosis hypoxia for an PaO2 of 70 mmHg. But this 
method is less sensitive in the diagnosis of mild degree of HPS(28). Arterial 
blood gas analysis in both sitting and supine position with breathing room air 
required for confirmation of HPS. The most sensitive marker is the increased 
alveolar arteriolar oxygen gradient (PA-aO2). Cut-off values of PaO2 < 80 
mmHg or PA-aO2 > 15 mmHg have been recommended for the diagnosis of 
HPS. In patients older than 64 years cut off value values of PaO2 < 70 mmHg or 
PA-aO2 > 20 mmHg are suggested (29). 
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Demonstration of intrapulmonary vasodilatation:  
Two methods are available to define the intrapulmonary vasodilatation (IPVD). 
1) Contrast echocardiography (CE) by microbubble using agitated saline 
2) Radioactive lung perfusion scan using macroaggregated albumin (MAA) 
 
Bubble contrast echocardiography is more sensitive and less invasive than the 
other. It is also easily available as compared to albumin scan. Bubble contrast 
echo also has advantage of excluding intracardiac shunting(30).  It has therefore 
a choice for screening of HPS. However it must be noted that all those 
diagnosed to have IPVD by CE may not demonstrate hypoxemia in ABG. In 
general subclinical HPS patient do not become hypoxemic over time to be 
considered as HPS(31). In bubble contrast echocardiography, a sample of 
normally saline is vigorously agitated to produce microbubbles, and then 
injected into a vein and at the same time tranthoracic echocardiography is being 
done to look for the appearance of microbubble in the right heart. Normally, 
these bubbles of size > 25 micrometer in diameter do not cross alveolar 
capillary bed as they are trapped in the comparatively smaller diameter capillary 
bed (5–8 micrometer). Appearance of micro bubble in the left heart after 
intravenous injection suggests that they have been allowed by the dilated 
pulmonary vessels to reach the left side of the heart. A positive study can of 
course also occur in patients with cardiac defect like atrial and ventricular septal 
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defect, but in this case appearance of bubble in the left heart will be much 
sooner (within three cycles) after their first appearance in the right atrium.  
 
 
Figure 2: Transthoracic Echocardiographic Features of hepatopulmonary 
syndrome. (RA: right atrium, LA: left atrium, RV: right ventricle, LV: left 
ventricle). (The contrast-enhanced echocardiograms show right atrial and right 
ventricular opacification with microbubbles immediately after injection of 
microbubble and delayed opacification of the left atrium and left ventricle, 
respectively.) 
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MAA perfusion lung scan is done by injection of technetium-99 m radio 
labelled MAA particles into the peripheral vein, followed by scanning of the 
whole body to estimate the extra pulmonary shunt fraction. These radio-labelled 
particles of diameter of 10–90 mm and are trapped in the normal pulmonary 
circulation. Thus, the detection of a significant amount of radiation in the brain 
or kidneys suggests intrapulmonary vasodilatation or intracardiac shunting. One 
drawback of this study is unable to differentiate between extra cardiac and 
intracardiac shunting. It is a highly specific but less sensitive than bubble 
contrast echo for detecting IPVD consistent with HPS and in the absence of 
hypoxemia it usually unable to detect intrapulmonary vasodilatation (30). At the 
same time it can quantify the amount of intrapulmonary vasodilatation in 
contrast to CE which has the advantage of being high sensitivity(30). 
 
Diagnosis of hepatopulmonary syndrome: 
________________________________________________ 
1) Liver disease 
2) Alveolar-arterial oxygen gradient >15 mmHg  
3) Demonstration of intrapulmonary shunting  
_________________________________________________ 
 
 
Prognosis:  
Cirrhotic patients with HPS have higher mortality as compared to the patients 
without HPS with the same severity of liver dysfunctions (32)(27). Five years 
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survivability of patients with HPS not underwent liver transplantation is only 
23% compared to patients without HPS(33). Survivability also depends on the 
severity of HPS. Severe HPS that is PaO2 < 60 usually have very bad prognosis 
and most of them died within 6 months(32). That’s why extra MELD points 
have been allocated to these groups of patients while listing for liver transplant. 
All these patients may not die respiratory failure but it has been noted that most 
of them died due to liver failure and its complications. 
 
Treatment: 
Liver transplantation is the only available effective therapy for the HPS. Several 
pharmacologic therapies have been tried in different uncontrolled trial with 
unsuccessful result(34). 
Medical therapies: 
1) Garlic preparation(35) 
2) Nitric oxide inhibitors(36) 
3) Pentoxifyllene(37) 
4) Cycloxygenase inhibitors 
5) Systemic glucocorticoids 
6) Cyclophosphamide 
 
Liver transplantation is the only effective treatment options available for HPS. 
Survival after liver transplantation is similar to the patients undergoing 
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transplantation without HPS except for those with severe hypoxemia (PaO2 
<60%). Patients with severe hypoxemia noted to have increase peri-transplant 
and post transplant mortality and also the increase interval between resolution 
of hypoxemia and transplantation. Long term survivability is not much different 
from the patients without HPS after liver transplantation(12). Hypoxemia is the 
only strongest predictor of mortality after liver transplantation(38). Because of 
poor outcome without liver transplantation diagnosis of hepatopulmonary 
syndrome with less than 60 mm of Hg has been given a priority for liver 
transplantation(39). Recently published data suggests improving outcome after 
liver transplantation in patients with HPS due to better postoperative care 
particularly in the immediate post transplant period. Mortality of only 9% has 
been reported in a recently published trial included patients with severe HPS 
(PaO2 < 50 mmHg).  
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Hydrogen sulphide: 
Hydrogen sulphide (H2S) is a colourless, water soluble gas with unpleasant 
smell of rotten egg(40). It is a small molecule and can permeate membranes 
freely (41). Endogeneous H2S is synthesized in various mammalian tissues from 
L cysteine by two enzymes, cystathion-β-synthetase (CBS) and cystathionine-γ- 
lyase (CSE), with the help of the co-factor pyridoxal-5-phosphate(42) . It was 
initially reported that H2S is a toxic gas and an environmental pollutant (40) 
with minor physiological or pathological significance. But, in recent years, H2S 
has gained importance as a physiological gaseous mediator, which is involved 
in many cell signaling processes(43) . Evidence indicates that H2S plays 
important roles in many pathological conditions such as hypertension, 
inflammation, edema, gastric mucosal ulceration and hemorrhagic shock(42). 
Inflammation is mediated by increased leukocyte adhesion to the injured site 
and H2S donors can suppress leukocyte adherence to the vascular endothelium 
and reduce leukocyte infiltration(44).  H2S is mainly metabolized to sulfate and 
thiosulfate via oxidation in the mitochondria. Rhodanese is a mitochondrial 
enzyme involved in the detoxification of H2S (45). Studies have shown that the 
administration of physiological level of H2S attenuates the myocardial injury 
and protects blood vessels and l 
29 
 
imits inflammation(46).
Enzymes involved in H2S biosynthesis 
Hydrogen 
sulphide
Cystathion
β synthase
Cystathion
γ lyase
3-
mercaptopyr
-uvate 
synthetase
 
Figure 3: Enzymes involved in H2S biosynthesis 
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Figure 4: Enzymatic and non enzymatic pathways of hydrogen sulphide (H2S) 
production (CBS: cystathion-β-synthetase, CSE: cystathionine-γ- lyase, MST: 3 
mercapto pyruvate synthetase ) 
 
Various studies have shown protective effect of H2S in colonic mucosal healing 
in inflammatory bowel disease(47). 
 
Role of H2S in portal hypertension has been studied in the recent past by 
Fiorucci et al and decrease level of tissue level was found in the patients with 
portal hypertension and also there has been decrease in the expression of 
cystathion gamma lyase at the tissue level in patients with portal 
hypertension(41).   The biological mechanism and pathways of sulphide Norris 
et al has shown the effect of H2S on the hepatic microcirculation and 
contribution of H2S in microcirculatory dysfunction during sepsis(48).  Fiorucci 
et al first investigated the H2S role in patients with portal hypertension(41). 
They demonstrated that expression of CSE in hepatocytes and hepatic stellate 
cells (HSCs) also known as Ito cells, but importantly not in the sinusoidal 
endothelial cells (SECs) is important in the regulation of portal pressure. 
Norepinephrine infusion in a KATP channel dependent increase in hepatic 
resistance has been antagonised by hydrogen sulphide by infusing NAHS. It 
was concluded that endogenous H2S would function as a vasodilator, preserving 
blood flow. Work by Norris et al.(49) Mentioned that H2S also have differential 
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effects on different sites of the liver like sinusoidal and presinusoidal levels. As 
liver contains both venous and arteriolar blood supply, regulation of hepatic 
microvasculature is complex. Intricate interplay of multiple vasoregulators 
along with hepatic sinusoidal cells, sinusoidal endothelial cells and kupffer cells 
contribute to hepatic blood flow regulation.  Normal sinusoidal pressure is being 
maintained by combined effect of endothelin-1, nitric oxide and carbon 
monoxide. Endothelial ET-1 binds to the ETA receptor, which is primarily 
expressed by HSCs(50). Sinusoids are surrounded by these cells and contraction 
of these cells lead to reduction in sinusoidal blood flow. Endothelial nitric oxide 
synthase activation and subsequent relaxation of sinusoids occurred by 
endothelial nitric oxide synthase (eNOS) after binding to endothelin B1 
receptors which were expressed by sinusoidal endothelial cells. Constitutively 
expressed parenchymal heme oxygenase-2 (HO-2) is responsible for the 
maintatinance of basal carbon monoxide level. Increase in intracellular cyclic 
guanosisne monophosphate after intraction with guanylyl cyclase is done by 
both NO and CO. NO has been shown to limit the release of ET-1 and to 
increase the expression of endothelial HO-1 (51).  
 
Signalling pathways involved in the pro-angiogenic effect of H2S:  
Activation of multiple signalling pathways to initiate angiogenesis 
1) PI-3K/Akt axis(52)  
2) MAPK pathway (extracellular signal related kinase ERK ½ and p38(53) 
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3) Modulation of hypoxia inducible factor 1α (HIF-1α)(54) 
4) Up-regulation of VEGF expression(53) 
5) Opening of KATP channels(55) 
 
 
 
Figure 5: Pathway of angiogenesis  
 
Yang et al demonstrated that VEGF signalling which is dependent on H2S, act 
by increasing intracellular calcium level and subsequent increase in CSE 
activity by calcium calmodulin pathway(56). Whatever may be the mechanism 
role of H2S has been established in the vasodilatory, anti-inflammatory and 
angiogenic activity.  
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AIM 
 
 
Aim 1: To study the prevalence of hepatopulmonary syndrome in the patients 
with cryptogenic chronic liver disease. 
Aim 2: To elucidate association of plasma hydrogen sulphide with 
hepatopulmonary syndrome in patients with cryptogenic chronic liver disease. 
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METHODOLOGY 
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Study Design: Observational study 
Study Period: March 2012 to January 2014 
Study Setting: Department of Hepatology 
   Christian Medical College 
 
Study patients:  
All patients with cryptogenic chronic liver disease were enrolled prospectively 
in this study. Cryptogenic chronic liver disease was diagnosed as per following 
criteria- 
1) Presence of chronic liver disease with or without portal vein thrombosis 
as evidenced by clinical, biochemical, radiologic and endoscopic findings 
2) Etiological evaluations for viral (HBsAg and anti HCV antibody), 
autoimmune (Serological profiles like ANA, ASMA, Anti LKM, AMA 
and SLA), wilson’s disease (Serum ceruloplasmin, 24 hour urinary 
copper and KF ring), haemochromatosis (ferritin and percentage of 
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transferring saturation) and non alcoholic fatty liver disease (bdy mass 
index and metabolic syndrome) have been excluded. 
 
 
Exclusion criteria:  
1) Significant pulmonary abnormality e.g. massive pleural effusion and 
obstructive airway disease. 
2) Presence of intracardiac shunt like atrial and ventricular septal defect. 
3) Inability to get informed consent 
Consent: Informed consent was taken from all the patients 
Study protocol was approved by Institutional review board (IRB) 
 
Methods:  
Demographic data:  
 Demographic data like age, gender and residence were collected. 
Baseline investigations:  
The following base line investigations were done in all study subjects 
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1) Etiological workup for chronic liver disease ( Viral serology for hepatitis 
B and C, if negative autoimmune profile that included 
ANA,SLA,LKM,SMA, Wilson’s workup that included 24 hours urine 
copper and serum ceruloplasmin, Iron studies) 
2) Ultrasonography of abdomen and Doppler of hepatic vein, portal vein, 
splenic vein and inferior vena cava. 
3) Gastroscopy to assess varices. 
4) Ascitic fluid analysis if ascites was present. 
5) Liver biopsy either percutaneous or transjugular route as indicated on a 
case to case basis. 
6) Baseline biochemical investigations like liver function tests and renal 
function test, alpha fetoprotein, prothombin time with INR and complete 
blood counts. 
 
Evaluation for HPS in study patients: 
All study patients underwent arterial blood gas (ABG) analysis and contrast 
echocardiography (CE) to look for the evidence of hypoxemia and 
intrapulmonary vasodilatation (IPVD) respectively. 
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Arterial blood gas analysis for the determination of alveolar and arteriolar 
oxygen gradient P (A-a) O2:  
 Arterial blood gas sample was obtained by percutaneous radial artery 
puncture with the subject in a standing position (at least for 5 minutes) 
breathing room air and was analysed with a standard blood gas analyser (BG 
Electrolytes, Instrumentation Lab. Inc., USA). Determination of difference 
between alveolar oxygen pressure (PAO2) and arterial oxygen pressure (PaO2) 
was done using following formula:  
  PAO2-PaO2 = (FIO2 [Patm–PH2O] – [PaCO2/0.8]) – PaO2,  
§ PAO2: partial pressure of alveolar oxygen 
§ PaO2: partial pressure of arterial oxygen 
§ FIO2: fraction of inspired oxygen 
§ Patm: atmospheric pressure 
§ PH2O: partial pressure of water vapour at body temperature 
§ PaCO2: partial pressure of arterial carbon dioxide  
(0.8 corresponds to the standard gas-exchange respiratory ratio at rest); the 
normal range is 4 to 8 mm Hg (0.5 to 1.1 kPa) 
The normal range for the partial pressure of oxygen is 80 to 100 mm Hg (10.7 
to 13.3 kPa) at sea level, while the patient is at rest and breathing ambient air.  
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Contrast echocardiography (CE):  
 Contrast echocardiography (CE) was performed by using a General 
Electric echocardiography device with 3- and 5-MHz probes with patients lying 
in a supine position. Intravenous access was done in right cubital vein.  Agitated 
saline was used to produce microbubble of >10 micrometer diameter and was 
injected in the right arm. Appearance of microbubble within three to six cycles 
after appearance of the same in right heart signifies intrapulmonary 
vasodilatation (IPVD). Normally diameter of pulmonary capillaries are less 
enough to restrict these microbubble to pass through the capillaries which is less 
than 8 to 15 micrometer.  
Study patients were classified into three groups on the basis of ABG and CE 
findings as mentioned below. 
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 NO HPS SUBCLINICAL 
HPS 
HPS 
P (A-a) O2 Normal  Normal Abnormal  
Contrast 
Echocardiography 
Normal Abnormal  Abnormal  
 
Study patients were also grouped as No IPVD (negative contrast 
echocardiography) and IPVD (positive contrast echocardiography). Patients 
Study patients
NO HPS
(Normal ABG and 
CE)
SUBCLINICAL HPS
(Abnormal ABG 
and normal CE)
HPS
(Both ABG and CE 
abnormal)
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with IPVD that is positive contrast echocardiography were divided into mild 
and moderate to severe according to the filling of the right heart three cycles 
after appearance of contrast in the left heart. It was considered as mild when 
less than 25% of the right heart was filled by contrast agent and moderate to 
severe if it is more than 25%.   
 
 
everity of HPS was defined by the following criteria: 
Degree of 
severity 
Alveolar-arterial oxygen 
gradient [P (A-a) O2 ] 
partial pressure of oxygen 
(PaO2 ) 
Mild  ≥15 mm Hg  ≥80 mm Hg 
Moderate ≥15 mm Hg  ≥60 to <80 mm Hg 
Severe ≥15 mm Hg  ≥50 to <60 mm Hg 
Very severe ≥15 mm Hg  <50 mm Hg 
Adapted from reference no : N Engl J Med 2008; 358:2378-87. 
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Measurement of Plasma H2S Level:  
 Blood sample (5ml) was collected from the subjects and H2S levels in 
plasma was measured spectrophotometrically ten minutes of collection of blood 
sample according to following method. 100µl of aliquots of the samples was 
mixed with 50µl of distilled water in micro-centrifuge tubes containing 300µl of 
zinc acetate (1% w/v) to trap H2S. The reaction was terminated after 5 min by 
adding 200µl of N, N-2dimethyl-p-phenylenediamine sulphate (20mM in 7.2 M 
HCl) and immediately followed by addition of 200µl of FeCl3 (30mM in 1.2 M 
HCl). The mixture was kept in the dark for 20 minutes. In order to precipitate 
protein from the samples 150µl of trichloroacetic acid (10% w/v) was added. 
The mixture was then centrifuged at 10,000 rpm for 10 minutes. The absorbance 
of the resulting supernatant was measured at 670 nm using a 96-well plate 
reader (Bio-Tek instruments, INC, USA). Finally, H2S concentration in the 
plasma was calculated against the calibration curve of standard H2S solutions 
(NaHS: 3.125-100 µM).   
Potential bias:   
Consecutive patients were included in the study to exclude selection bias. 
Another potential source of bias would be the difference in aetiology of chronic 
liver disease, so only patients with cryptogenic liver disease with or without 
portal vein thrombosis were included. 
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Statistical analysis: 
Sample size: Study design was an observational study. With an assumption that 
20% would be the prevalence of hepatopulmonary syndrome in patients with 
cryptogenic CLD patients sample size of approximately 20 patients in each 
group with total of 60 patients with precision of 10% and desired confidence of 
95%. 
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Statistical Methods:  
Data were analysed using three groups:  
 NO HPS:    Normal PAO2- PaO2 and normal CE 
 SUBCLINICAL HPS:  Normal PAO2- PaO2 and abnormal CE 
 HPS:     Abnormal PAO2- PaO2 abnormal CE 
Continuous data was expressed as median and range and categorical data was 
expressed as number and percentage. The difference in H2S values were 
assessed by Mann-whitney U and Kruskal Wallis test in different groups. 
Plasma H2S level in patients with IPVD was compared to patients with no 
IPVD after adjusting for MELD score (binary logistic regression). 
Spearman correlation (ρ) was used to assess the correlation between MELD, 
PaO2and H2S. 
For all comparisons, statistical significance was defined as a P value less than 
0.05. 
Funding:  
Fluid research grant, Christian Medical College. 
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Prevalence of HPS in study patients: 
Total no of study patients: 58 
Number of patients without HPS (NO HPS): 24 
Number of patients with subclinical HPS (SUBCLINICAL HPS): 21 
Number of patients with HPS (HPS): 13  
 
Figure 3: Distribution of patients in three groups 
Severity of HPS in study patients: 
Severity of HPS among study patients according to PaO2 were mentioned in 
figure 2. Severity was defined by the following criteria:  
1) Mild – PaO2 ≥ 80% 
2) Moderate - PaO2 ≥ 60% - <80% 
3) Severe - PaO2 ≥ 50% - <60% 
4) Very severe - <50% 
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Five patients had moderate and four had mild HPS. Severe and very severe HPS 
was noted in two patients each. 
 
Figure 4: Severity of HPS according to PaO2 (n=13) 
  
0
2
4
6
MILD MODERATE SEVERE VERY SEVERE
48 
 
Demographic data of the study patients :  
Median age of 58 study patients was 45 years (range 16-74 years). Median age 
of the patients without HPS, with subclinical HPS and with HPS was 46, 46 and 
40 years respectively. There were predominantly male in all three groups. 
Table 1: Demographics in study patients (n=58) with cryptogenic chronic 
liver disease:  
 Total 
(n=58) 
No HPS 
(n=24) 
Subclinical 
HPS 
(n=21) 
HPS 
(n=13) 
Age in years 
Median (Range) 
45 (16-74) 46 (25-69) 46(20-74) 40 (16-68) 
Gender (M:F) 45:13 16:8 17:4 12:1 
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Clinical parameters: 
Clinical features associated with the patients with HPS are shown in table ... 
Dyspnoea was noticed in only two patients (one in the subclinical and other in 
the HPS group). Cyanosis was observed in one patient with HPS. Only one 
patient in the HPS group had spider naevi. Clubbing was noted in 5 patients (2 
in the subclinical and 3 in the HPS group).  
Table 2: Clinical parameters in the study subjects (n=58) 
 Study patients 
(n=58) 
No HPS 
(n=24) 
Subclinical 
HPS  
(n=21) 
HPS  
(n=13) 
Cyanosis  1 0 0 1 
Clubbing 5 0 2 3 
Spider naevi  1 0 0 1 
Dyspnoea  2 0 1 1 
 
Baseline laboratory parameters: 
Consecutive patients with cryptogenic chronic liver disease were included in the 
study. Patients with HPS had higher prothombin time and lower albumin level 
as compared to other groups. There was thrombocytopenia in all the three  
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groups with lowest in the group with HPS. Haemoglobin and aminotransferase 
level was similar in all three groups. 
Table 3: Baseline laboratory parameters in the study patients (n=58) 
 Study patients 
(n=58) 
No HPS 
(n=24) 
Subclinical 
HPS (n=21) 
HPS (n=13) 
Haemoglobin 
(gm/dl)  
11 (6.1-15.5) 11.2 (6.7-
14.8) 
10.2 (6.1-
15.5) 
12 (7.8-15.5) 
Albumin 
(gm/dl) 
3.4 (1.3-4.8) 3.5 (2.3-4.8) 3.1 (1.3-4.1) 2.9 (2.2-4.6) 
Platelet count 
x 103 / cu. mm 
78 (18-268) 95 (36-268) 72 (18-193) 55 (22-106) 
Serum 
bilirubin 
(mg/dl) 
2.3 (0.3-17.8) 1.7 (0.3-4.9) 2.6 (0.6-17.8) 3.1 (0.7-5.5) 
AST (u/L) 49 (16-102) 44 (16-88) 53 (32-102) 51 (20-75) 
ALT (u/L) 29 (2-117) 30 (2-117) 30 (11-85) 25 (8-54) 
PT (seconds) 14.1 (11-24) 12.9 (11.1-
17.7) 
14.5 (11-19.2) 15.7(12.8-24) 
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, PT: 
Prothombin time 
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Liver disease severity and oxygenation in study patients: 
Most of the patients in all three groups were in Child’s class A. Overall Child’s 
class A, B and C in all the three groups were 30, 18 and 10 respectively. There 
was more number of patients with child’s class C in the subclinical group of 
patients as compared to others. The median MELD score in three groups were 
11, 13 and 14 respectively. In patients with HPS median MELD score was 14 
with a range of 10 to 20 which was higher than other two groups. Low PaO2 
was noted in the patients with HPS as compared to others. 
Table 4: Child’s class, MELD and PaO2 in study patients:  
 Study patients 
(n=58) 
No HPS 
(n=24) 
Subclinical 
HPS (n=21) 
HPS (n=13) 
Child’s class 
(A/B/C) 
30/18/10 14/9/1 9/5/7 7/4/2 
MELD score 
Median 
(range) 
12 (7-27) 11 (7-16) 13 (7-27) 14 (10-20) 
PaO2 92 (42-138) 93.8 (42-138) 98.5 (83-127) 76 (42-133) 
MELD: Model for End Stage Liver Disease, PaO2: Partial pressure of oxygen 
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Figure 5: Child's class status in three groups 
 
Prevalence of IPVDs, Hypoxia and hepatopulmonary syndrome:  
Intrapulmonary vasodilatation (IPVD), as defined by microbubble opacification 
of the left atrium within three to six cardiac cycles after right-atrial 
opacification,  was noted in 34 patients by contrast echocardiography. 13 
patients had hypoxemia (PaO2 <80%) on ABG. All patients with hypoxemia had 
demonstrable IPVD on contrast echocardiography. HPS was diagnosed in these 
thirteen patients. Chest X ray was normal in all of the patients.  
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Figure 6: Percentage of patients with IPVD, hypoxia and HPS among study 
patients (n=58) 
 
 
Plasma hydrogen sulphide level in the different groups: 
Plasma hydrogen sulphide level was 12.3, 19.6 and 19.5 in patients without 
HPS, with subclinical HPS and with HPS respectively. As compared to patients 
with no HPS, patients with subclinical HPS had higher H2S levels (p-value: 
0.03) and there was a trend to higher H2S in patients with HPS (p-value: 0.3). 
Plasma level of H2S level was similar in patients with subclinical HPS and HPS.  
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Table 5: Plasma H2S in different groups (n=47) 
 Study 
patients 
(n=47) 
No HPS 
(n=19) 
Subclinical 
HPS (n=20) 
HPS (n=8) P value 
Plasma H2S 
(µmol/L) 
Median 
(range) 
16.4 (0-83) 12.3 (0-47) 19.6 (5.7-83) 19.5 (6.4-
64.3) 
0.09 
HPS : Hepatopulmonary syndrome 
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Figure 7: Plsma H2S in different study patients (n=47) 
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Plasma H2S, PaO2 and MELD score in patients with and without IPVD: 
According to contrast echocardiography finding study patients were divided 
into two groups i.e. with IPVD and without IPVD. Plasma H2S level was 
significantly higher in the patients with IPVD (p=0.03). After adjusting for 
MELD score, there was trend, albeit not reaching statistical significance, 
towards higher H2S levels in patients with IPVD as compared to patients with 
no IPVD (p-value : 0.07) 
Table 6: Plasma H2S, PaO2 and MELD in patients with IPVD and without 
IPVD 
 With IPVD (n-34) Without IPVD (n=24) 
MELD  
Median (Range) 
13 (7-27) 10 (7-16) 
pAO2 (mm of Hg) 
Median (Range) 
91.5 (42-133) 93.8 (42-138) 
H2S (µmol/L) 
Median (Range) 
19.6 (5.7-83) 12.3 (0-47) 
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Figure 8: Plasma H2S, PaO2 and MELD in patients with IPVD and without 
IPVD 
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Plasma H2S level in the different grades of IPVDs: 
Subjective assessment of the appearance of contrast in the left heart after 
injection of contrast in the right cubital vein was done. It was considered mild 
when less than 25% of the right heart was filled with contrast and more that that 
was considered moderated to severe. Increase in the severity of IPVD was 
associated with higher level of H2S level (13.2 Vs 26.1) although this difference 
was not statistically different. 
Table 7: Plasma H2S level in the different grades of IPVDs: 
 Mild (<25%) 
(n=10) 
Moderate to severe 
(>25%) (n=17) 
P value 
H2S 13.2 (5.7-47) 26.1 (5.7-64.3) 0.07 
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Figure 9: Plasma H2S level in the different grades of IPVDs 
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Correlation between Plasma H2S level, PaO2 and MELD 
On bivariate correlation analysis, there was a moderate positive correlation 
between MELD score H2S levels (ρ = 0.47; p-value: 0.001). There was no 
correlation between H2S (ρ: -0.13-; p-value: 0.39) and MELD score (ρ:-0.94; p-
value: 0.49) to PaO2. 
 
 
Figure 10: Correlation between plasma H2S, PaO2 and MELD score 
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DISCUSSION 
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In this study we enrolled consecutive cryptogenic chronic liver disease patients 
with or without portal vein thrombosis to study the prevalence of HPS. We 
found the frequency of subclinical HPS and HPS was 36.2% and 22.4% 
respectively. IPVD was detected in 59% of the study patients.  
We also noted a higher plasma H2S levels in patients with subclinical HPS as 
compared to patients with no HPS. In patients with HPS, H2S levels were 
similar to patients with subclinical HPS. This may be secondary to less number 
of patients with HPS in the study group. Significantly higher plasma H2S level 
was also noted in patients with IPVD as compared to patients without IPVD. 
This difference in the plasma H2S level was not significant after adjusting 
MELD score may be due to less number of patients in the HPS group. Positive 
correlation noted between MELD score and plasma H2S levels needs further 
larger studies to corroborate.  
There are very few studies regarding the prevalence of HPS in patients with 
chronic liver disease. It has been estimated to be around 10 to 30% patients 
undergoing evaluation for liver transplantation. As patients are not evaluated for 
the HPS unless they are symptomatic in the form of dyspnoea, cyanosis or 
clubbing; we tend to underestimate the true prevalence. In our prospective 
study, even in predominantly Child’s class A patients the prevalence of HPS 
was 22%. In addition, 59% patients had demonstrable IPVD. The prognosis, 
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quality of life and further natural history in these patients needs to be elucidated 
in a follow up cohort study.   
Screening for HPS is done by contrast echocardiography for IPVD and ABG to 
look for the evidence of hypoxemia. Another modality to detect the presence of 
IPVD is 99m technetium aggregated albumin scan which is less sensitive as 
compared to contrast echocardiography in detecting IPVD(1). We used contrast 
echocardiography in our study. Semi quantitative assessment of contrast density 
was done subjectively to determine the grade of IPVD(2).   
Subclinical HPS is the form of HPS where patient has a detectable IPVD 
without hypoxia. These patients may need frequent monitoring for the 
development of hypoxemia and overt HPS. The strategy of follow up is not well 
characterised and needs further research.  
Although clinical outcomes are similar in patients with or without IPVD after 
liver transplantation(3). Mimidis et al studied in 75 patients with CLD with 
Child class A and B for the evidence of IPVD by CE. Eight of 75 (10.7%) 
patients had a positive CE without evidence of hypoxemia(4). In a study by 
Shafiq et al frequency of subclinical and overt HPS were 13.2% and 15.8% 
respectively(5). In the same study all of patients with HPS were CTP class C 
and HCV related cirrhosis. Prevalence also varies depending on the cut off for 
arterial oxygenation used for the diagnosis of HPS. In a study by Schenk et al 
the prevalence of HPS was considerably higher using alveolar arteriolar oxygen 
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difference as an indication of hypoxemia. The prevalence was considerably 
higher using P(A-a)O2 (>15 mm Hg, 32%; >20 mm Hg, 31%; and >age related 
threshold, 28%) than using reduced partial pressure of arterial oxygen PaO2 as a 
threshold (<80 mm Hg, 19%; <70 mm Hg, 15%; and <age related threshold, 
15%)(6). Prevalence of HPS was also noted to be higher in patients with CLD 
as compared to patients with extra hepatic portal venous obstruction (EHPVO) 
(18.5% Vs 4%)(7). In our study prevalence of subclinical HPS and HPS was 
noted to be higher than the previously reported. IPVD was noted to be more 
common in patients with alcoholic cirrhosis and with advanced liver 
dysfunction(1). Similarly frequency of HPS is much higher in cirrhosis than in 
extrahepatic portal venous obstruction(7). In the same study by Gupta et al child 
class and portal vein diameter were the only two risk factors significantly 
associated with the development of IPVD.  
 
Role of various vasodilatory gaseous transmitters like NO and CO have been 
evaluated in the pathogenesis of HPS. Although role of H2S was studied in the 
setting of portal hypertension its role in HPS has not been studied. H2S is 
considered to be a vasodilator and also plays a role in angiogenesis(8). It has 
been shown that CSE derived H2S is involved in the maintenance of portal 
venous pressure. The reduction of CSE expression in the liver with cirrhosis 
contributes to the development of increased intrahepatic resistance and portal 
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hypertension(9). Precapillary and capillary pulmonary vasodilation and 
angiogenesis are the two important mechanism in the development of IPVD and 
subsequent HPS.  
Significant difference in the level of plasma H2S was noted in patients with and 
without IPVD (p=0.03) suggest possible role of H2S as a vasodilator in IPVD. 
H2S level was also much higher in patients with moderate to severe IPVD as 
compared to patients with mild IPVD. 
Mucosa of the small and large intestine produces H2S In the small and large 
intestine(10). Many of the bacteria within the lumen can produce H2S in close 
proximity to the epithelium(11). The colonic mucosa can detoxify H2S that it is 
exposed to(12). In this way intestinal epithelium can produce H2S along with it 
may serve as metabolic barrier to the diffusion of bacteria derived H2S into the 
lamina propria(13). Within the epithelium, H2S is rapidly inactivated by a 
complex of mitochondrial enzymes collectively referred to as the “sulfide 
oxidation unit”(14).  Colonocytes can adapt itself to utilyze H2S as an energy 
source and at the same time it has the ability to detoxify the same(15)(16)(17).  
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CONCLUSIONS 
 
· In 59% patients of cryptogenic cirrhosis there was a demonstrable IPVD.  
· The prevalence of HPS in patients with cryptogenic cirrhosis was 22%. 
· Plasma H2S levels were higher in patients with IPVD and HPS as 
compared to patients with no IPVD or HPS.  
· This finding in predominantly Child’s class A cirrhotic argues the role of 
H2S in pathogenesis of HPS and needs further studies. 
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1 613308D WILLIAM s 2 51 M NO NO NO NO NO
NORM
AL 7.1 75000 3.9 1.8 6.4 3.7 44 29 116 17.2 1.58 C 19 96 13.7
POSITI
VE 25 48.93
2 883110D
PATNAM S 
RAO s 2 40 M YES NO YES NO NO
NORM
AL 11 26000 18 16 4.3 1.9 90 38 55 19.2 1.91 1.29 C 27 96
POSITI
VE 83
3 287217F PACHIYAPAN s 2 65 M NO NO NO NO NO
NORM
AL 6.8 174000 1.2 0.7 5.2 1.3 34 20 90 11 1.01 C 20 97 10.2
POSITI
VE 25 47.14
4 460640C RATNA KUMAR s 2 38 M NO YES NO NO NO
NORM
AL 10 19000 2.6 1.3 6.7 3.4 64 36 115 16.8 1.52 C 16 113
POSITI
VE 25 31.43
5 421799D SAMPATH s 1 69 M NO NO NO NO NO
NORM
AL 9.8 87000 0.5 0.2 5.9 2.4 16 2 44 11.8 1.08 2.58 B 16 110
NEGAT
IVE 25.71
6 667115C GOPAL s 2 55 M NO NO NO NO NO
NORM
AL 8.2 23000 2.5 1 6 2.5 90 59 74 15.8 1.45 0.9 C 12 100 13.4
POSITI
VE 25 46.43
7 816337D SHEFALI s 1 55 F NO NO NO NO NO
NORM
AL 8.7 60000 0.7 0.3 6.9 2.8 30 20 83 11.4 1.05 0.88 A 7 98
NEGAT
IVE 0
8 350644F BEER MD s 1 32 M NO NO NO NO NO
NORM
AL 15 268000 1.2 0.5 7.8 4.7 33 20 95 14.3 1.3 1.03 A 10 97
NEGAT
IVE 8.46
9 352684F
SHIVA 
PRASAD n 2 62 M NO NO NO NO NO
NORM
AL 11 38000 2.3 1.3 7.3 3.1 59 24 106 14.4 1.31 0.89 A 13 127
POSITI
VE 10 10.77
10 289410F
SUNIL KR 
PRASAD n 1 51 M NO NO NO NO NO
NORM
AL 11 128000 1.5 0.8 8.9 2.6 44 19 80 14.6 1.33 1.7 B 16 138
NEGAT
IVE 12.31
11 255130F
KISHORI 
SWARNAKAR n 1 48 M NO NO NO NO NO
NORM
AL 11 105000 0.7 0.3 8.2 4.4 42 47 122 12.3 1.12 1 A 8 98
NEGAT
IVE 8.57
12 999215D SELVI s 1 26 F NO NO NO NO NO
NORM
AL 11 75000 1.4 0.3 9 4.8 51 39 227 12.5 1.14 0.92 A 9 105
NEGAT
IVE 5
13 402796F PREMLAL s 3 28 M NO NO NO NO NO
NORM
AL 9.1 24000 1.9 1.1 7.3 2.8 75 54 214 12.8 1.17 0.98 A 11 88.5 17.8
POSITI
VE 25 56.43
14 245981F
SHANTI PADA 
CHAKRAVARTI n 2 61 M NO NO NO NO NO
NORM
AL 12 55000 0.6 0.3 8.5 3.8 59 37 79 11.6 1.06 0.98 A 7 83
POSITI
VE 25 7.14
15 359961F
SATHYAMOOR
THY s 1 63 M NO NO NO NO NO
NORM
AL 6.7 136000 0.5 0.2 5.4 3.2 21 8 66 13.6 1.24 1.24 B 11 99
NEGAT
IVE 8.57
16 360974F
SUBBA 
RATNAM s 2 45 M NO NO NO NO NO
NORM
AL 0.6 0.4 6.8 3 68 32 131 12.1 1.11 1.07 A 8 107
POSITI
VE 10 5.71
17 913094D RENUGOPAL s 2 74 M NO NO NO NO NO
NORM
AL 7 144000 1 0.6 5.6 2.2 66 52 118 13.2 1.2 1.4 C 14 115
POSITI
VE 50 17.14
18 358396F URMILA JHA n 2 62 F NO NO NO NO NO
NORM
AL 11 123000 2.4 1.9 6.2 2.4 63 32 107 13.6 1.24 1.3 B 15 87
POSITI
VE 25 5.71
19 361792F
SEKH BABAR 
ALI n 1 51 M NO NO NO NO NO
NORM
AL 10 87000 0.4 0.2 7.5 3.4 38 15 145 11.5 1.05 1.02 A 7 96
NEGAT
IVE
20 386379F PRADEEP n 1 52 M NO NO NO NO NO
NORM
AL 15 130000 2.3 0.6 7.5 4.6 79 117 103 11.5 1.05 1.21 A 12 101
NEGAT
IVE 15.71
21 417404F
RANJIT 
PATHAK n 2 41 M NO NO NO NO NO
NORM
AL 7 193000 0.8 0.3 8.6 3.5 32 11 100 14.2 1.29 1.16 A 11 98
POSITI
VE 25 16.43
22 424142F
LELLAPALLI 
VENKATA 
SUBBAIAH s 3 27 M NO NO NO NO NO
NORM
AL 11 106000 3.1 1.5 8 3.9 56 22 129 13.6 1.24 0.8 A 13 79
POSITI
VE 10 6.43
23 416260F
SAIBAL 
KUMAR DATTA n 3 49 M NO NO NO NO NO
NORM
AL 14 81000 4 1.6 7.3 3.1 45 11 226 15.1 1.37 0.83 B 14 48
POSITI
VE 50 64.28
24 330111F
KRISHNA 
SHARMA n 2 36 M NO NO NO NO NO
NORM
AL 16 45000 3 0.9 7 3.4 102 85 99 15.8 1.43 0.88 B 15 94
POSITI
VE 25
25 400167D RAMESH C s 2 36 M NO NO NO NO NO
NORM
AL 6.1 53000 1.4 0.3 5.4 2.4 35 16 41 16.2 1.47 0.98 B 12 100
POSITI
VE 25 37.86
26 301248F
LAKHO PATI 
DEVI n 1 37 F NO NO NO NO NO
NORM
AL 12 52000 1.8 0.7 7.6 4.7 50 42 71 12 1.1 0.68 A 10 99
NEGAT
IVE 47.14
27 287608D
NEELAM 
MISHRA n 2 42 F NO NO NO NO NO
NORM
AL 12 18000 1.8 0.6 7.7 3.9 34 17 129 11.4 1.04 0.67 A 9 89
POSITI
VE 10 47.14
28 438995F
BIPLAB KANTI 
CHOWDHURI n 3 35 M NO NO NO NO NO
NORM
AL 11 60000 1.7 0.7 6.9 4.4 44 19 181 13 1.19 0.85 A 10 88 16.9
POSITI
VE 10
29 324396F
USHA DEVI 
GUPTA n 1 44 F NO NO NO NO NO
NORM
AL 9.4 106000 3.1 3 6.3 2.6 88 46 117 17.7 1.6 0.85 B 16 112
NEGAT
IVE 7.86
30 457494F
PRATIMA 
CHAKRABORT
Y n 2 41 F NO NO NO NO NO
NORM
AL 8.6 99000 0.9 0.6 7.8 3.4 36 21 74 14 1.27 0.9 A 9 87
POSITI
VE 25 20.71
31 282818F
RAKESH 
KUMAR 
GERARI n 2 29 M NO NO NO NO NO
NORM
AL 12 43000 2.1 0.7 7.1 3.6 39 20 141 15.4 1.4 0.82 A 13 89
POSITI
VE 25 26.1
32 049872D ARUN KUMAR n 2 38 M NO NO NO NO NO
NORM
AL 10 30000 3 0.6 6.1 2.7 34 19 83 16.7 1.51 0.7 B 15 89
POSITI
VE 10 16.43
33 472273F
RAJESH 
SONAR n 1 38 M NO NO NO NO NO
NORM
AL 9 54000 1.2 0.5 5 2.8 23 5 53 12.4 1.13 0.91 B 8 96
NEGAT
IVE 12.14
34 449735F PARO DEVI n 1 41 F NO NO NO NO NO
NORM
AL 9.8 105000 0.7 0.5 7.3 3 23 10 88 11.7 1.07 1.05 B 8 91 16
NEGAT
IVE 21.1
35 454856F MD FAZAL P n 3 24 M NO NO NO NO NO
NORM
AL 11 26000 5.5 3 6.6 2.9 52 12 109 15.6 1.42 1.16 B 18 58
POSITI
VE 50 24.67
36 447117F ANIL MUNDA n 2 20 M NO NO NO NO NO
NORM
AL 14 122000 0.6 0.2 7.2 4 39 24 94 12.6 1.15 0.97 A 8 95
POSITI
VE 10 30.71
37 433905F ALAMELU s 1 50 M NO NO NO NO NO
NORM
AL 11 77000 4.8 2.5 7.4 2.3 78 22 125 15.1 1.37 0.91 C 16 91
NEGAT
IVE 15.71
38 201250B SANKARI V s 2 42 F NO NO NO NO NO
NORM
AL 12 50000 1 0.8 6.7 3.1 40 11 217 13 1.19 0.69 B 8 95 11
POSITI
VE 10 15
39 494961F MD LOKMAN n 1 40 M NO NO NO NO NO
NORM
AL 12 132000 4.9 0.5 7.5 4.4 56 43 103 11.6 1.06 0.98 B 13 57 48
NEGAT
IVE 21.43
40 379830F
ADEM 
SESHGIRI s 3  M NO YES NO NO NO
NORM
AL 15 69000 3.4 0.9 7.6 4.6 28 17 85 13 1.18 0.94 A 13 66 positive 50 6.67
41 756857C JEYALAKSHMI s 3 43 F YES YES NO YES NO
NORM
AL 13 30000 3.4 1.4 6.2 2.4 59 8 120 17.4 1.56 0.8 B 17 78 40.6
POSITI
VE 50 28.57
42 612267F MATHEW s 3 55 M NO NO NO NO NO
NORM
AL 12 74000 4.4 1.7 6 3 64 30 56 18.2 1.63 1.12 B 16 68
POSITI
VE 25
43 369432F
SHYAMAL KR 
SAHOO n 1 52 M NO NO NO NO NO
NORM
AL 11 72000 1.9 0.8 8.3 4.1 43 47 62 12.4 1.13 0.89 A 10 98
NEGAT
IVE
44 371206F
JAMUNA 
PRASAD n 1 50 M NO NO NO NO NO 
NORM
AL 14 46000 2 0.6 9.1 3.6 41 18 80 13.5 1.23 1.1 A 12 97
NEGAT
IVE 18.57
45 262086F
JHARESWAR 
NAYAK n 1 57 M NO NO NO NO NO
NORM
AL 12 97000 0.5 0.2 8.2 4 27 13 70 11.1 1.02 1.08 A 7 110
NEGAT
IVE 14.29
46 323326f SK DOLON n 1 31 M NO NO NO NO NO
NORM
AL 12 85000 0.5 0.2 7.5 4 58 50 205 11.7 1.07 1.08 A 7 100
NEGAT
IVE 28.57
47 149839F RABIN BAG n 1 54 M NO NO NO NO NO
NORM
AL 14 68000 1.7 0.6 7.3 3.7 84 67 132 12.7 1.16 1.36 B 10 88 18
NEGAT
IVE
48 633532F SARITA DEVI n 1 25 F NO NO NO NO NO
NORM
AL 7.5 36000 3.8 0.6 5.7 3.3 27 15 49 13.8 1.25 0.46 B 14 42
NEGAT
IVE
49 681191F SWAROOP n 3 16 M NO YES NO N YES
NORM
AL 9.8 4.1 2.7 57 37 318 16.7 1.5 0.75 A 16 88 23
POSITI
VE 50
50 787345D JOY JOSE s 2 57 M NO YES NO N N
NORM
AL 9.7 66000 2.4 1.3 6.3 3 46 20 136 15.2 1.38 1.07 C 15 115 -2
POSITI
VE 10 18.57
51 699746F RAJENDRAN s 3 56 M NO NO NO N N
NORM
AL 15 78000 3.4 1.4 6.2 2.6 58 37 133 15.4 1.39 1 C 15 73.7 44.9
P0SITI
VE
52 068105F
MATHEW 
VERGHESE s 3 68 M NO N NO N N
NORM
AL 11 55000 3.5 1.5 6.1 2.2 59 21 121 24 2.12 0.69 C 20 59.2 52.2
POSITI
VE 50
53 706559F
SHAIK 
KHALEEL n 3 36 M NO N NO N N
NORM
AL 16 22000 1.6 0.7 7.3 3.9 20 13 99 14.5 1.31 0.94 A 11 42
POSITI
VE 50 14.29
54 494572F
BIRENDRA 
YADAV n 2 31 M NO N NO N N
NORM
AL 13 48000 3.1 0.5 6.9 4.1 33 25 53 14.2 1.29 0.83 A 13 97
POSITI
VE 10 10.83
55 648000F
RAJESH 
PANDEY n 3 40 M NO N NO N N
NORM
AL 7.8 38000 0.7 0.4 6.5 2.4 50 41 128 14.7 1.33 0.84 A 10 83
POSITI
VE 10 11.43
56 093521F SANCHITA n 1 48 F NO N NO N N
NORM
AL 12 52000 1.8 0.8 7.9 4.5 44 12 130 14.9 1.36 1.04 A 12 95
NEGAT
IVE 6.67
57 302051D
MANOJ 
KUMAR n 1 38 M NO N NO N N
NORM
AL 14 127000 2 0.8 6.8 3.4 49 38 108 12.9 1.16 0.85 A 11 46
NEGAT
IVE 0
58 064554F NURUJEN s 1 47 F NO N NO N N
NORM
AL 9.7 86000 0.3 0.1 6 3.4 18 9 88 11.9 1.09 0.92 A 7 86
NEGAT
IVE
